ClinicalTrials.gg
RecruitingNCT05620940Updated Sep 15, 2025

A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects.

A Phase 1 interventional study of Vivitrol Injectable Product and IVL3004 in Opioid Dependence, Alcohol Dependence and Multiple Sclerosis, sponsored by Inventage Lab., Inc.. Recruiting at 1 site in Australia. Open to male participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-09-15.

Sponsored by Inventage Lab., Inc. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Dec 2025, 10 months ago, but the record still lists the study as recruiting.
  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
40
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
Male
01

Study summary

A Clinical Trial to Assess Pharmacokinetic Profiles, Safety and Tolerability of IVL3004 and IVL4002 in Healthy Male Subjects.

Read the detailed description

A Phase 1, Open-Label, Exploratory, Fixed-Sequence, Pharmacokinetic Single Acending Dose Study of IVL3004 Versus Vivitrol® (Naltrexone) Long-Acting Injectable(LAI) and IVL4002 in Healthy Subjects

02

Conditions studied

  • Opioid Dependence
  • Alcohol Dependence
  • Multiple Sclerosis
03

In context

Opioid-Related Disorders

1,476 studies on the registry are indexed under Opioid-Related Disorders; 293 are open to participants now.

This study's planned enrollment of 40 is below the median of 63 across 1,170 interventional studies indexed under Opioid-Related Disorders.

Browse Opioid-Related Disorders studies →

Lead sponsor

Inventage Lab., Inc. is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Healthy adult male, ≥18 and ≤55 years of age, non-smokers or occasional smokers (defined as smoking less than 10 cigarettes or nicotine equivalent per week, and willing to abstain from smoking during confinement at the clinical site).
  2. ≥18.0 and ≤32.0 kg/m2 and body weight ≥55.0 kg.
  3. Healthy as defined by:

    1. The absence of illness, infection, or medical/surgical procedure within 4 weeks prior to dosing or planned inpatient surgery (including dental surgery) or hospitalization during the study period.
    2. The absence of clinically significant history of neurological, endocrine, cardiovascular, respiratory, hematological, immunological (including ), psychiatric, gastrointestinal, renal, hepatic, and metabolic disease.
  4. Subjects who are not vasectomized for at least 3 months prior to dosing, and who are sexually active with a female partner of must be willing to use one of the following acceptable methods from dosing and for 90 days after dosing:

    a. Simultaneous use of a male condom and, for the female partner, hormonal contraceptives used for at least 4 weeks or intrauterine device placed for at least 4 weeks prior to dosing.

  5. Subjects who have had a vasectomy must be willing to use a condom until study exit.
  6. Subjects who practice abstinence from sexual intercourse as a usual and preferred lifestyle.
  7. Subjects must be willing not to donate sperm for 90 days after dosing.
  8. Willing to undergo SC abdominal injection or IM ventral gluteal injection to allow for drug administration.
  9. Willing and able to provide written after the nature of the study has been explained and prior to the commencement of any protocol- specific study procedures.

Exclusion criteria

Exclusion Criteria:

  1. Any abnormal finding at physical examination at screening or Day -1.
  2. Clinically significant abnormal laboratory test results at screening or Day -1, or positive serology test results for (HIV), or virus at screening.
  3. Is prone to skin rashes, irritation, or has a skin condition such as recurrent eczema that is likely to impact the injection site area or demonstrates any abnormal skin tissue in the proposed injection area, as determined by the Investigator.
  4. Any history of or neoplastic disease.
  5. History of significant allergic reactions (e.g., drug reaction, anaphylactic reaction, , angioedema) to any drug, or to any present in the formulations.
  6. , AST, or total >1.5x (ULN) at screening or Day -1.
  7. Estimated (eGFR) \<60 mL/min/1.73m2 as calculated by the 2021 Chronic Kidney Disease-Epidemiology (CKD-EPI) equation at screening or Day -1.
  8. Clinically significant abnormalities ( >450 ms or PR interval >220 ms) or vital sign abnormalities (systolic blood pressure \<90 or >140 mmHg, diastolic blood pressure \<40 or >90 mmHg, or heart rate \<40 or >100 bpm) at screening or Day -1.
  9. History of alcohol abuse within 1 year prior to screening or regular use of alcohol within 6 months prior to screening that exceeds 14 units of alcohol per week (1 unit = 375 mL of beer 3.5%, 100 mL of wine 13.5%, or 30 mL of spirit 40%), or positive alcohol test at screening or Day -1.
  10. History of drug abuse within 1 year prior to screening or positive test for drugs of abuse (e.g., phencyclidine, opiates, benzodiazepines, barbiturates, amphetamines, methamphetamines, cocaine, and tetrahydrocannabinol) at screening or Day -1.
  11. Presence of any underlying physical or psychological (e.g., depression) medical condition that, in the opinion of the Investigator, would make it unlikely that the participant will comply with the protocol or complete the study per protocol. Mild depression and anxiety that has been resolved at least 6 months prior to screening is accepted.
  12. Use of medications for the timeframes specified below, with the exception of hormonal and medications exempted by the Investigator on a case-by-case basis because they are judged unlikely to affect the PK profile of the study drug or subject safety:

    1. Depot injection or implant within 3 months prior to dosing;
    2. Strong CYP inhibitors or inducers within 30 days prior to dosing;
    3. Prescription medications within 14 days prior to dosing;
    4. Any vaccine, including COVID-19 vaccine, within 7 days prior to dosing;
    5. OTC medications (including topical and nasal formulations with active pharmaceutical ingredients) within 7 days prior to dosing, except for occasional use of acetaminophen/paracetamol (up to 2 g/day);
    6. Natural health products (including herbal remedies, homeopathic and traditional medicines, probiotics, food supplements such as vitamins, minerals, amino acids, essential fatty acids, and protein supplements used in sports) within 7 days prior to dosing;
    7. Anesthetic agents within 24 hours prior to dosing.
    8. Anticoagulant medications from 15 days prior to dosing to 6 weeks post- dose.
  13. Participation in a clinical research study involving the administration of an or marketed drug or device within 30 days prior to dosing, administration of a biological product in the context of a clinical research study within 90 days prior to dosing, or concomitant participation in an investigational study involving no drug or device administration.
  14. Donation of plasma within 7 days prior to dosing or donation or loss of 500 mL or more of whole blood within 30 days prior to dosing.
  15. Any reason which, in the opinion of the Investigator, would prevent the subject from participating in the study.
Terms in these criteria, in plain language(19)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
40 participants (estimated)

Study arms

  • Active comparator
    Part A Group 1 (Vivitrol Injection)

    Vivitrol, Single Dose, IM injection

    Drug: Vivitrol Injectable Product

  • Experimental
    Part A Group 2 (IVL3004 A mg)

    IM, Single Dose

    Drug: IVL3004

  • Experimental
    Part A Group 3 IVL3004 B mg)

    IM, Single Dose

    Drug: IVL3004

  • Experimental
    Part B Group 1 (IVL4002 Cmg)

    SC, Single Dose

    Drug: IVL4002

Interventions

  • DrugVivitrolStudies of VivitrolVivitrol pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Naltrexone Long-Acting Injection

  • DrugIVL3004

    Naltrexone Long-Acting Injection

  • DrugIVL4002

    Naltrexone Long-Acting Injection

06

What researchers measure

Primary outcomes

  1. AUC0-240

    Area under the concentration-time curve from time zero to 240hrs

    Time frame: Pre-dose, up to Day 57

  2. Cmax

    The maximal observed concentration

    Time frame: Pre-dose, up to Day 57

  3. AUC240-672

    Area under the concentration-time curve from time 240 to 672hrs

    Time frame: Pre-dose, up to Day 57

  4. AUC0-672

    Area under the concentration-time curve from time zero to 672hrs

    Time frame: Pre-dose, up to Day 57

  5. AUC0-inf

    Area under the concentration-time curve from time zero to infinity

    Time frame: Pre-dose, up to Day 57

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2024 (actual). Primary completion is estimated for Dec 2025, 15 months after the start.

Of 79 phase 1 interventional studies under Opioid-Related Disorders, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 9 and three quarters within 33. This study's planned 15 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 10, 2022
First posted
Nov 17, 2022
StartActual
Sep 11, 2024
Primary completionEst.
Dec 30, 2025
CompletionEst.
Dec 30, 2025
Last update
Sep 15, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 15, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05620940
Lead sponsor
Inventage Lab., Inc.
Responsible party
Sponsor
First posted
Nov 17, 2022
Start date
Sep 11, 2024
Primary completion
Dec 30, 2025 (estimated)
Completion
Dec 30, 2025 (estimated)
Last update
Sep 15, 2025

Study contacts

HyeRyeon Kim
Contact
hr.kim@inventagelab.com
82-31-608-0514 ext. 5134
Heesun Kim
Contact
flower@inventagelab.com
82-31-608-0514 ext. 5134

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion